Skip to content

Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF

Efficacy and Safety of Preemptive Intravenous Dexamethasone in MIS-TLIF

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06367855
Acronym
MIS-TLIF
Enrollment
60
Registered
2024-04-16
Start date
2024-05-01
Completion date
2025-12-31
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disc Degeneration, Disc Disease, Fusion of Spine, Spinal Stenosis Lumbar, Surgery

Brief summary

Researchers are considering Dexamethasone as preemptive medication before minimally invasive spine fusion surgery to minimize postoperative back pain with minimal side effects, aiming to enhance the effectiveness of surgery and improve patient outcomes.

Detailed description

Surgery for spine fusion through a minimally invasive technique called MIS-TLIF has become increasingly popular nowadays due to various reasons such as lower blood loss and reduced need for blood transfusions, less postoperative back pain, and shorter surgical duration compared to the traditional technique known as TLIF. However, even after MIS TLIF, patients still experience issues such as wound or back pain, which can affect their physical activity and increase the risk of infection. Prolonged hospital stays lead to resource wastage. In the Enhanced Recovery After Surgery (ERAS) program for spine surgery, preoperative medication, including Acetaminophen, NSAIDs, and Gabapentinoids, is recommended to alleviate postoperative back pain. However, even after implementing ERAS, patients undergoing MIS TLIF still experience pain, suggesting that further pain reduction strategies are needed. The use of Dexamethasone as preemptive medication has shown promising results in various surgeries, with minimal side effects and a manageable cost. Dexamethasone, administered via injection, has a longer duration of action compared to other steroids, making it suitable for preemptive use. The main objective is to study the effectiveness of using Dexamethasone via intravenous injection before minimally invasive spine fusion surgery, known as MIS-TLIF, in reducing postoperative back pain. The secondary objectives are to compare the rate of morphine usage for pain management after surgery between two groups. To compare the side effects and adverse reactions of the medication, such as nausea and vomiting, surgical site infection rates, and blood sugar levels post-surgery. To compare the fusion rates of the spinal bones. To compare the length of hospital stays after surgery.

Interventions

DRUGDexamethasone

long-acting corticosteroid IV route

DRUGNormal saline

normal saline

Sponsors

Potsawat Surabotsopon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
50 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* Age range: 50-80 years old. * Undergoing MIS TLIF surgery at 1-2 spinal levels.

Exclusion criteria

* Previously undergone spine surgery. * HbA1C greater than or equal to 7.5 mg% * Allergic to all types of experimental medication. * History of using systemic steroids.

Design outcomes

Primary

MeasureTime frameDescription
effectiveness of dexamethasone24 hours, 2 weeks, 6 weeks, 12 weeks post operative periodpostoperative VAS score at rest and motion for back pain

Secondary

MeasureTime frameDescription
Morphine consumption24 hours post operative periodrate of morphine usage for pain management
Complication24 hours, 2 weeks, 6 weeks, 12 weeks post operative periodTo compare the side effects and adverse reactions of the medication, such as nausea and vomiting, surgical site infection rates, and blood sugar levels post-surgery
Fusion rate6monthsTo compare the fusion rates of the spinal bones
Length of hospital stay1 yearTo compare the length of hospital stays after surgery.

Countries

Thailand

Contacts

Primary ContactKonthorn Chankong, Master's degree
gearkonthorn@gmail.com+66859496902

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026